Sarepta Therapeutics’ (SRPT) Rating Downgrade Dents Share Price

We recently published a list of 10 Stocks Investors Dumped Fast. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against other worst-performing stocks.

Sarepta Therapeutics declined by 7.67 percent on Monday to close at $39.71 each as investors unloaded portfolios amid the generally cautious market environment, while waiting for concrete developments from the ongoing US-China trade negotiations.

Additionally, investors may have sold off positions following the previous day’s gains, boosted by Scotiabank’s rating upgrade for its stock to “outperform” from “sector perform” previously.

The upgrade represented a vote of confidence amid the stock’s 68-percent year-to-date drop, dented by safety concerns linked to the death of a young male from taking its Elevidys drug.

Additionally, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported a disappointing earnings performance in the first quarter of the year, having swung to a net loss of $447.5 million from a $36.1 million net income in the same period last year, despite revenues jumping by 80 percent to $744.9 million from $413.5 million year-on-year.

A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals.

Looking ahead, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said it expects lower revenues for full-year 2025, at $2.3 billion to $2.6 billion versus the $2.9 billion to $3.1 billion as expected previously.

Overall, SRPT ranks 4th on our list of worst-performing stocks. While we acknowledge the potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.